West Pharmaceutical Services (WST) Heads To CPHI Milan 2026 With Senior Leaders Speaking

• West Pharmaceutical Services (NYSE:WST) is presenting at the CPHI Milan 2026 conference, a major global pharma gathering.
• Senior leaders from West Pharmaceutical Services are scheduled to speak on business development topics with industry and potential partners in attendance.
• The company is also highlighting its self injection systems portfolio to an international audience of drug makers and device developers.
• There is more to West Pharmaceutical Services than its CPHI Milan 2026 conference presentations for investors to weigh. We have also spotted 2 other big wins worth knowing about at West Pharmaceutical Services.

For a broader view on where drug delivery and medical technology trends may intersect with pricing gaps, explore 27 high quality undervalued stocks.

West Pharmaceutical Services sits in life sciences as a specialist in containment and delivery systems for injectable drugs, selling into pharma and healthcare customers across the Americas, EMEA, and Asia Pacific. This makes a global industry forum like CPHI Milan directly relevant to its customer base and product focus.

See which insiders are buying and selling West Pharmaceutical Services following this latest news.

What CPHI Milan signals for the West Pharmaceutical Services story

The West Pharmaceutical Services narrative leans on the idea that higher value components and services become a bigger share of what the group sells, especially into complex drugs like GLP 1 therapies and biologics, with execution in West Vantage contract work as the key swing factor.

"The key factor is successful execution on higher margin opportunities such as drug handling and other value-added work in West Vantage, while maintaining HVP capacity, quality and pricing..."

See how the full story points towards a $405 fair value for West Pharmaceutical Services.

CPHI Milan puts West Pharmaceutical Services directly in front of global drug developers at a time when its thesis leans heavily on high value components and self injection formats. Having senior leaders speak to business development and showcase self injection systems points toward the mix shift that analysts link to more resilient margins versus primary packaging peers like Gerresheimer or Schott Pharma.

The event also touches the more fragile part of the story, which is execution in value added services such as drug handling inside West Vantage. If discussions in Milan translate into programs that use West for finishing, inspection or contract work, that counters the risk flagged in the narrative that exiting older manufacturing contracts could leave a profitability gap.

In the end, this conference appearance matters only to the extent that it nudges West Pharmaceutical Services closer to, or further away from, the multi year margin and mix story you already believe.

Add West Pharmaceutical Services to your Watchlist and get alerts as these catalysts play out.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com